APYX Apyx Medical Corp
Price Chart
Executive Summary
Apyx Medical announced the publication of a small (22-patient) investigator-initiated study in Aesthetic Surgery Journal Open Forum showing that combining Avli subcision with Renuvion helium plasma radiofrequency improved cellulite and skin laxity at 180 days. Up to 81.8% of patients showed visible improvement, with histological evidence of increased collagen and elastin in a subset. This is a routine clinical-data press release with no financial figures, no regulatory submission, and no revenue impact — a modest marketing milestone for the Renuvion platform.
Actionable Insight
This is a routine clinical-data press release with no near-term revenue catalyst. Monitor for any subsequent FDA submissions or commercial partnership announcements tied to the Avli + Renuvion combination, but no trading action is warranted on this filing alone.
Key Facts
- 22-patient prospective investigator-initiated study published in Aesthetic Surgery Journal Open Forum
- Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment
- Combination approach: Avli (Tiger Aesthetics Medical) for subcision + Renuvion for helium plasma radiofrequency
- Histological analysis in a subset showed increased collagen and elastin with improved dermal architecture
- No financial data, no regulatory filing, no revenue or earnings guidance provided in the filing
Financial Impact
No financial figures disclosed; immaterial clinical-data publication
Risk Factors
- Small sample size (n=22) limits statistical significance and generalizability
- Investigator-initiated study — not a company-sponsored pivotal trial
- No FDA submission or clearance path disclosed for the combination approach
- No revenue or adoption metrics provided to quantify commercial impact
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018098 |
| Exhibit: ex_966637.htm | 0001437749-26-018098 |
| Document: 0001437749-26-018098-index-headers.html | 0001437749-26-018098 |
| Document: 0001437749-26-018098-index.html | 0001437749-26-018098 |
| Document: 0001437749-26-018098.txt | 0001437749-26-018098 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
24d ago
|
8-K
| $4.13 $3.96 | ▼ −4.12% | ▼ −5.77% | $4.69 (+13.56%) |
|
May 21, 2026
24d ago
|
Press Release
| $4.25 $4.15 | ▼ −2.35% | ▼ −3.95% | $4.69 (+10.35%) |
|
May 14, 2026
4w ago
|
8-K
| $4.36 $4.25 | ▼ −2.52% | ▼ −1.81% | $4.69 (+7.57%) |
|
May 11, 2026
4w ago
|
8-K
| $3.92 $3.87 | ▼ −1.28% | ▼ −1.19% | $4.69 (+19.64%) |
|
Apr 23, 2026
7w ago
|
Press Release
| $3.80 $3.46 | ▼ −8.95% | ▼ −10.43% | $4.69 (+23.42%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $3.45 $3.74 | ▲ +8.41% | ▲ +9.31% | $4.69 (+35.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access